Management of Mycosis Fungoides-type Cutaneous T-cell Lymphoma (MF-CTCL): Focus on Chlormethine Gel

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Apr 10

PMID 30962713

Citations 12

Authors

Daphne Denis

Nathalie Beneton

Kamel Laribi

Herve Maillard

Affiliations

Soon will be listed here.

Abstract

Mycosis fungoides (MF) is a low-grade cutaneous lymphoma accounting for more than half of primary cutaneous T-cell lymphomas (CTCLs). Due to the rarity of CTCL, randomized studies are lacking, and treatment is based mainly on the recent published European Organisation for Research and Treatment of Cancer guidelines. Basically, early-stage MF is treated with skin-directed treatments, whereas advanced-stage MF requires more aggressive therapies. Among the skin-directed therapies, nitrogen mustard has been used for more than 50 years. A gel formulation was developed recently, showing a slight decrease in efficacy, counterbalanced by better tolerance (essentially due to a decrease in delayed hypersensitivity reactions). This review aims to summarize the current management of MF and the role of chlormethine gel in the treatment of the disease.

Citing Articles

Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation.

Alberti-Violetti S, Ardigo M, Massone C, Pileri A, Sala R, Teoli M Front Oncol. 2024; 13:1298296.

PMID: 38239642 PMC: 10794371. DOI: 10.3389/fonc.2023.1298296.

Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events.

Bhatti S, Joffe D, Banner L, Talasila S, Mandel J, Lee J Front Med (Lausanne). 2024; 10:1243459.

PMID: 38164221 PMC: 10758200. DOI: 10.3389/fmed.2023.1243459.

Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoides.

Pena J, Cull D, Strowd L, Vaidya R, Seegars M, Ahn C Leuk Lymphoma. 2023; 64(13):2202-2207.

PMID: 37671707 PMC: 10873100. DOI: 10.1080/10428194.2023.2254435.

Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing.

Giuliano C, Frizzarin S, Alonzi A, Stimamiglio V, Ortiz-Romero P Dermatol Ther (Heidelb). 2022; 12(11):2517-2529.

PMID: 36229764 PMC: 9588113. DOI: 10.1007/s13555-022-00813-y.

Determination of Alteration in Micromeritic Properties of a Solid Dispersion: Brunauer-Emmett-Teller Based Adsorption and Other Structured Approaches.

Singh L, Kaur L, Singh G, Dhawan R, Kaur M, Kaur N AAPS PharmSciTech. 2022; 23(6):209.

PMID: 35902454 PMC: 9333898. DOI: 10.1208/s12249-022-02367-w.

References

Jones G, Kacinski B, Wilson L, Willemze R, Spittle M, Hohenberg G . Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002; 47(3):364-70. DOI: 10.1067/mjd.2002.123482. View

Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G . Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003; 101(11):4267-72. DOI: 10.1182/blood-2002-09-2802. View

Kim Y, Martinez G, Varghese A, Hoppe R . Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003; 139(2):165-73. DOI: 10.1001/archderm.139.2.165. View

Heald P, Mehlmauer M, Martin A, Crowley C, Yocum R, Reich S . Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003; 49(5):801-15. DOI: 10.1016/s0190-9622(03)01475-0. View

Zackheim H, Kashani-Sabet M, McMillan A . Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003; 49(5):873-8. DOI: 10.1016/s0190-9622(03)01591-3. View

Olsen E . Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther. 2003; 16(4):311-21. DOI: 10.1111/j.1396-0296.2003.01643.x. View

Girardi M, Heald P, Wilson L . The pathogenesis of mycosis fungoides. N Engl J Med. 2004; 350(19):1978-88. DOI: 10.1056/NEJMra032810. View

Willemze R, Jaffe E, Burg G, Cerroni L, Berti E, Swerdlow S . WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10):3768-85. DOI: 10.1182/blood-2004-09-3502. View

Demierre M, Taverna J . Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006; 55(3):543-4. DOI: 10.1016/j.jaad.2006.04.025. View

10.

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R . Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment.... Blood. 2007; 110(6):1713-22. DOI: 10.1182/blood-2007-03-055749. View

11.

Olsen E, Kim Y, Kuzel T, Pacheco T, Foss F, Parker S . Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25(21):3109-15. DOI: 10.1200/JCO.2006.10.2434. View

12.

Whittaker S, Demierre M, Kim E, Rook A, Lerner A, Duvic M . Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010; 28(29):4485-91. DOI: 10.1200/JCO.2010.28.9066. View

13.

Agar N, Wedgeworth E, Crichton S, Mitchell T, Cox M, Ferreira S . Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010; 28(31):4730-9. DOI: 10.1200/JCO.2009.27.7665. View

14.

Beylot-Barry M, Dereure O, Vergier B, Barete S, Laroche L, Machet L . [Management of cutaneous T-cell lymphomas: Recommendations of the French Cutaneous Lymphoma Group]. Ann Dermatol Venereol. 2010; 137(10):611-21. DOI: 10.1016/j.annder.2010.06.021. View

15.

Olsen E, Rook A, Zic J, Kim Y, Porcu P, Querfeld C . Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2010; 64(2):352-404. DOI: 10.1016/j.jaad.2010.08.037. View

16.

Stern R . The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012; 66(4):553-62. DOI: 10.1016/j.jaad.2011.04.004. View

17.

Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M . Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 3:22-31. DOI: 10.1111/j.1468-3083.2012.04520.x. View

18.

Trautinger F, Just U, Knobler R . Photopheresis (extracorporeal photochemotherapy). Photochem Photobiol Sci. 2012; 12(1):22-8. DOI: 10.1039/c2pp25144b. View

19.

Lessin S, Duvic M, Guitart J, Pandya A, Strober B, Olsen E . Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2012; 149(1):25-32. PMC: 3662469. DOI: 10.1001/2013.jamadermatol.541. View

20.

Lindahl L, Fenger-Gron M, Iversen L . Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study. Br J Dermatol. 2013; 170(3):699-704. DOI: 10.1111/bjd.12620. View